Market Place
Sourcing Support
Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
20 Feb 2024 //
PR NEWSWIRE
Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint
16 May 2023 //
PR NEWSWIRE
Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint
01 Jun 2022 //
PRNEWSWIRE
Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR
08 Apr 2022 //
PRNEWSWIRE
Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
10 Nov 2021 //
CLINICALTRIALSARENA
Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
09 Nov 2021 //
CLINICALTRIALSARENA
Iterion begins phase 1 trial of tegavivint to treat AML
21 Oct 2021 //
PHARMABIZ
Iterion Initiates Enrollment of Ph2a Dose Expansion Study of Tegavivint
28 Jul 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.